Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
3 evidence topics · 4 sources
Investigational dosage form: 25 mg and 50 mg oral capsules
| Field | Quoted record |
|---|---|
| International nonproprietary name | “Obefazimod” |
| Strengths | “25 mg capsule”; “50 mg capsule” |
| Route of administration | “Oral” |
| Packaging | “Each blister card (=kit) contains 35 capsules.” |
| Blister cards | “IMP will be packaged in child-resistant blister cards with blinded labels.” |
Pharmaceutical forms in the EU paediatric investigation plan: hard capsule and an age-appropriate oral liquid
| Field | Quoted record |
|---|---|
| Pharmaceutical forms | “Capsule, hard”; “Age-appropriate oral liquid dosage form” |
| Route of administration | “Oral use” |
| Quality-related study | “Development of an age-appropriate oral liquid dosage form.” |
Pediatric 50 mg minitablet formulation compared with the adult capsule in healthy participants (ABX464-911)
Commercial dosage form and strengths
No evidence found.